David S. Hong, MD, discusses the potential of moving tisotumab vedotin (HuMax-TF-ADC) to the frontline setting in cervical cancer.
David S. Hong, MD, deputy chair, Department of investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the potential of moving tisotumab vedotin (HuMax-TF-ADC) to the frontline setting in cervical cancer.
Results from the phase II innovaTV 201 trial showed that tisotumab vedotin is very active in patients with heavily pretreated, metastatic cervical cancer, Hong explains. In the updated analysis of the phase II trial, tisotumab vedotin demonstrated an overall response rate of 22% and a median progression-free survival of 4 months, says Hong.
Several ongoing studies are now looking at tisotumab vedotin in later lines of therapy, but eventually the hope is to combine the agent with other drugs such as bevacizumab (Avastin) or pembrolizumab. When there is a high response rate in refractory settings as tisotumab vedotin has demonstrated, the hope is that the agent will provide similar benefit in earlier lines of therapy, concludes Hong.